Project description:RNAseq is performed (50bp single end reads) on SW480, HT-29, HCT-15, HCT-116, COLO 205, and COLO 320 cell lines after DMSO or JQ1 treatment

2016-01-26 | GSE73318 | GEO

Cost implications of new treatments for advanced colorectal cancer.

Project description: Not available

| S-EPMC2875773 | biostudies-literature

Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data.

Project description: Not available

| S-EPMC8656546 | biostudies-literature

Transcription Factor Network Reveals New Treatments for Prostate Cancer Docetaxel Drug Resistance

Project description:Overcoming drug resistance is critical increasing the survival rate for prostate cancer (PCa). In this study, we modeled docetaxel resistance using two PCa cell lines, DU145 and PC3. We conducted both single cell and bulk RNA sequencing. We constructed a transcription factor (TF) network for the docetaxel sensitive and resistant variants for all cell lines and sequencing methods resulting in 8 networks. We identified shared edges and nodes that represent a shared TF network for PCa that modeled the changes after acquiring drug resistance. Using this shared TF network, we identified drivers of the resistant phenotype. Interestingly, the network constructed from the bulk sequencing dataset revealed different TF drivers of resistance compared with the network constructed from the single cells. We validated the results constructed from the single cells to demonstrate the validity of the single cell sequenced TF network. We targeted GABPA (only identified in the single cell constructed network) and successfully re-sensitized both cell lines to docetaxel treatment. Additionally, we conducted connectivity map analysis to identify potential drugs that disrupt the resistant networks. We identified trichostatin A as a potential combination treatment using the single cell sequenced network. Combination treatment of trichostatin A and docetaxel, both in vitro and in vivo PCa models decreased tumor growth. These results suggest by analyzing a population of resistant cells, identification of drivers and novel treatments is possible.

2023-04-01 | GSE149681 | GEO

Drug repurposing unveils new combinatorial treatments to treat mutant KRAS lung cancer

Project description:We report data on a drug combination with synergistic antitumor effect in KRAS-driven lung cancer. We used RNAseq to characterize the transcriptional changes elicited by each drug in a mutant KRAS lung cancer cell lines (H1792)

2023-08-10 | GSE161218 | GEO

The Construction of a Multi-Gene Risk Model for Colon Cancer Prognosis and Drug Treatments Prediction.

Project description: Not available

| S-EPMC11011764 | biostudies-literature

Comparative efficacy and tolerability of adjuvant systemic treatments against resectable colon cancer: a network meta-analysis.

Project description: Not available

| S-EPMC7739130 | biostudies-literature